Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Direct intrabone autologous stem cell infusion after ASCT
NL-OMON31554Phase 2Active, not recruiting
- Sponsor
- University Medical Center Groningen
- Start
- Jan 2009
- Modality
- Stem Cell Therapies → Cell Therapies
- Countries
- 1
01
Overview
Phase 2, open-label trial of autologous hematopoietic stem cells in multiple myeloma (MM) and lymphoma, sponsored by University Medical Center Groningen. Primary endpoints: Duration of granulocytopenia, Duration of thrombocytopenia and 5 more. Started Jan 2009; status: active, not recruiting.
02
Drugs
autologous hematopoietic stem cells
03
Conditions
multiple myeloma (MM)lymphoma
Beyond the preview
Go deeper on NL-OMON31554.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON31554.